Eli Lilly - Search News

Hosted on MSN · 6h

Why Eli Lilly and Company (LLY) is the Best Long-Term Growth Stock to Buy Now

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term growth stocks to buy right now.

Business Insider · 1d

Eli Lilly & Co (LLY) Gets a Buy from Truist Financial

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price

Investing.com on MSN · 1d

Eli Lilly announces $6.5 billion six-part note offering

Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered totaling $6.5 billion. The notes, which are collectively referred to as the "Notes",

Insider Monkey on MSN · 1d

Eli Lilly and Company (LLY): A Bull Case Theory

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)’s share was trading at $868.

Zacks.com on MSN · 2d

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +9.

Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

2d

Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

FierceBiotech6d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

6d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

5d

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

6don MSN

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

2d

Eli Lilly enters global license agreement with OliX for OLX75016

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

10d

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Fierce Biotech2d

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results